SAR Sareum Holdings Plc

TIDMSAR

RNS Number : 3826U

Sareum Holdings PLC

23 November 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Drawdown of Equity Prepayment Facility

Cambridge, UK, 23 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that it has drawn down on the GBP0.3 million Second Deposit in respect of the Equity Prepayment Facility announced on 3 August 2023.

In accordance with the terms of the Equity Prepayment Facility, the Company will issue 227,892 four year warrants over ordinary shares of 1.25p each exercisable at a price of GBP0.829337 to Riverfort.

Unless otherwise defined herein, all capitalised terms in this announcement shall have the meanings assigned to them in the Company's announcements of 3 August 2023.

For further information, please contact:

 
 Sareum Holdings plc 
  Tim Mitchell, CEO                                01223 497700 
  Lauren Williams, Head of Investor Relations      ir@sareum.co.uk 
 Strand Hanson Limited (Nominated Adviser) 
  James Dance / James Bellman                      020 7409 3494 
 Peel Hunt LLP (Joint Corporate Broker) 
  James Steel / Patrick Birkholm                   020 7418 8900 
 Hybridan LLP (Joint Corporate Broker) 
  Claire Noyce 
                                                   020 3764 2341 
  ICR Consilium (Financial PR) 
  Jessica Hodgson / Davide Salvi / Stella 
  Lempidaki                                        020 3709 5700 
 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFZMZMNZLGFZM

(END) Dow Jones Newswires

November 23, 2023 02:00 ET (07:00 GMT)

Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Sareum (LSE:SAR)
Gráfica de Acción Histórica
De May 2023 a May 2024